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Heparin was fractionated on an affinity column of bovine milk lipoprotein lipase (LpL) immobilized to 
Aft-i-Gel- 15. The bound heparin, designated high-reactive h parin (HRH), enhanced LpL activity, presum- 
ably by stabilizing the enzyme against denaturation. The unbound heparin fraction had no observable effect 
on the initial rate of enzyme activity. However, at longer times of incubation there was inhibition of LpL 
activity. LpL-specific HRH also showed ahigh, Ca2+-dependent precipitating activity towards human plas- 
ma low density lipoproteins (LDL). Since LpL and LDL both bind to heparin-like molecules at the surface 
of the arterial wall, we suggest that their similar heparin-binding specificity may have physiological conse- 
quences as it relates to the development of atherosclerosis. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Lipoprotein lipase (LpL) is a rate-limiting en- 
zyme in the removal of triglycerides from the cir- 
culation [l]. LpL is immobilized to the luminal 
surface of the capillary endothelia [2] by its in- 
teraction with specific cell membrane-associated 
heparin-like molecules [3-51. LpL also binds to 
heparin-Sepharose and to heparin in solution 
[6-lo]. In addition to LpL, triglyceride-rich 
lipoproteins and low density lipoproteins (LDL) 
also bind heparin [ 1 l- 131; the heparin-lipoprotein 
interaction is mediated by apolipoprotein B and 
apolipoprotein E [ 141. Since both LpL and 
lipoproteins bind heparin-like molecules, the pur- 
pose of this study was to determine if a LpL- 
specific heparin also associates with lipoproteins. 
The results show that a LpL specific heparin also 
binds apolipoprotein B. 
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Sodium heparin (lot no. PM 10983, 154 IU/mg) 
from porcine intestinal mucosa was a generous gift 
from Hepar Industries, Franklin, OH. Bovine milk 
LpL was purified to homogeneity by chromatog- 
raphy on heparin-Sepharose by the method of Kin- 
nunen [15] as modified by Socorro and Jackson 
[ 161. LpL-Affi-Gel-15 was prepared as follows: 
30 ml LpL (1.43 mg/ml) in 0.1 M Na phosphate, 
pH 7.5, 0.4 M NaCl, 0.5 M guanidine-HCl was 
added to 10 ml Affi-Gel-15 (Bio-Rad) equilibrated 
with 0.1 M Na phosphate, pH 7.5. After in- 
cubating overnight at 4°C with gentle mixing, the 
gel was incubated 4 h at room temperature with 
2.5 ml of 1 M ethanolamine, pH 8.0, to block 
unreacted sites. The gel was then washed with 
100 ml of 0.1 M NaHCO3, pH 8.0, 2 M NaCl; 
100 ml H20; and 100 ml of 10 mM Tris-HCl, pH 
8.0, 0.15 M NaCl, respectively. The gel was stored 
at 4°C in 10 mM Tris-HCl, pH 8.0, 0.15 M NaCl, 
0.01% NaNs. 
Heparin was quantitated by a modified car- 
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bazole reaction procedure [ 171. A turbidimetr~c 
assay was used to quantitate the heparin-mediated 
precipitation of LDL [4]; LDL were isolated from 
normal human plasma [18]. LpL activity towards 
~-nitrophenylbutyrate (PNPB) was determined by 
a modification of [19]. Time courses of the reac- 
tion were followed at 22OC by monitoring the pro- 
duction of p-nitrophenoxide (PNP) at 400 nm. 
The reaction mixtures contained 1 ml of 0.1 M Na 
phosphate, pH 7.25, 0.15 M NaCl, 0.5 mM 
PNPB, 8.45 pg LpL, and various amounts of 
heparin as indicated. Initial velocities were 
calculated from the slopes of the linear portion of 
each time course: 
Vi ~mol~min-’ -mg LpL-‘) = 
(lo6) (AA,&min)(l ml/1000 ml) 
6PNP (mg LPL) 
where AAs&min is the slope of the time course 
and EPNP is the absorptivity constant, 
14775 1 -M-l - cm-‘. The increase in absorbance 
due to the spontaneous hydrolysis of PNPB was 
subtracted from the incubation which included 
enzyme. 
3. RESULTS 
Fig. 1. Chromatography of heparin on LpL immobilized 
to Affi-Gel-15. Heparin (150 mg) in 10 ml of 10 mM 
Tris-HCl, pH 8.0,O.lS M NaCl was incubated with 5 ml 
LpL-Affi-Gel-15. The gel was poured into a column 
(2.5 x 9 cm) and eluted with the equilibration buffer. 
Heparin was eluted with 0.4 and 1.0 M NaCI, as 
indicated; 2-ml fractions were collected, Uranic acid 
(absorbance at 530 nm) was determined with 0.1 ml 
sample. Inset: HRH was rechromatographed over a 
second column of LpL-Affi-Gel-15 and eluted with 1 M 
NaCl as described above. The solid bars indicate the 
fractions that were pooled and used for subsequent 
Chromatography of crude heparin on a column 
of LpL immobilized to Affi-Gel-15 is shown in 
fig. 1. After the sample entered the gel, the column 
was washed with 10 mM Tris-HCl, pH 8.0,O. 15 M 
NaCl, followed by 0.4 M NaCl; unbound heparin 
is designated unreactive heparin (URH). High- 
reactive heparin (HRH) was eluted with 1 M NaCl. 
Based on uranic acid content, ~2% of the total 
heparin applied to the column was HRH. Heparin 
was not eluted with 1 M NaCl in control ex- 
periments performed with ethanolamine-substi- 
tuted Affi-Gel-15. Rechromatography of HRH 
showed that >95% of the HRH uranic acid again 
bound to the affinity column and was eluted with 
1 M NaCl (fig.1, inset). 
1.02 firno1 * min-’ - mg LpL-‘. LpL catalysis in 
both the absence of heparin or presence of URH 
was 0.81 pmol - min-’ - mg LpL-I. Moreover, the 
rates of catalysis decreased after 200 s, whereas in 
the presence of HRH the reaction was linear for up 
to 400 s. One possible explanation for the non- 
linearity of LpL catalysis in the absence of heparin 
is that LpL becomes denatured during the incuba- 
tion. Fig.2 (inset) shows that in the absence of 
heparin LpL loses >50% of its activity after 
20 min incubation. However, in the presence of 
HRH, LpL is stable for the full time scale of the 
enzyme assay. 
To examine the specificity of URH and HRH 
for LpL, we next determined the effect of the 
isolated heparin fractions on enzyme activity with 
PNPB as substrate. As is shown in fig.2, addition 
of HRH to the incubation mixture enhanced LpL 
activny. The initial rate (fig.2, loo-180 s) of LpL 
catalysis in the presence of HRH was 
It is known that heparin interacts with LDL to 
form insoluble complexes in the presence of Ca2+ 
[20]. Therefore, we next examined the binding of 
LpL-specific heparin and LDL with a tur- 
bidimetric assay. As shown in fig.3, HRH was 
?-times more effective than URH in precipitating 
LDL; 2.2 pg HRH resulted in 50% precipitation of 
LDL whereas > 15 pg were required for URH. 
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077 4. DISCUSSION 
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Fig.2. Effect of heparin on LpL catalysis. LpL activity 
was determined with PNPB as substrate as described in 
section 2. The incubation mixtures contained 0.5 mM 
PNPB, 4 pg URH or HRH, and 8.45 pg LpL in a final 
volume of 1.0 ml of 0.1 M Na phosphate, pH 7.25, 
0.15 M NaCI. Inset: effect of preincubation of LpL on 
enzyme activity in the absence- (o---o) and presence 
(G--zI) of HRH. LpL was incubated at 37”C, and 
enzyme activity was determined at the times indicated. 
1.411 
I I , I 
0 2 4 6 0 10 
Uranic Acid (ug) 
Fig.3. Precipitation of LDL by heparin. URH and HRH 
were incubated with LDL (150 gg protein) in 1 .O ml of 
10 mM Tris-HCI, pH 8.0, containing 10 mM CaC12. 
After 5 min at 37°C turbidity was determined by light 
scattering at 620 nm. 
Matsuoka et al. [21] and Bengtsson et al. [22] 
previously described the isolation of LpL-specific 
heparin by affinity chromatography on immobi- 
lized LpL. However, in those reports the effect of 
the isolated fractions on LpL activity was not 
assessed. It is well known 1231 that heparin stabi- 
lizes LpL activity. Our results show that the 
stabilization of LpL by heparin is specific for 
HRH. In contrast to HRH, URH inhibited LpL 
hydrolysis of PNPB. In this regard, Posner et al. 
[24] reported that high concentrations (l-2 mg/ 
ml) of crude heparin competitively inhibit the LpL- 
catalyzed hydrolysis of trioleoylglycerol. 
The binding of HRH to both LpL and LDL may 
be physiologically important as related to the 
development of atherosclerosis. It is well known 
that LDL binds to glycosaminoglycans within the 
arterial wall [25]. We speculate that LDL may 
compete with LpL for the same heparin-like recep- 
tors on endothelial cells, thereby reducing the 
amount of enzyme at the cell surface. A decrease 
in the amount of bound LpL could potentially lead 
to elevated levels of plasma remnant lipoprotein 
particles, which, in turn, may contribute to the 
process of atherogenesis [26]. 
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